



## Commercial/Healthcare Exchange PA Criteria

*Effective: June 3, 2020*

**Prior Authorization:** Palforzia

**Products Affected:** Palforzia (peanut allergen-dnfp) oral capsule, oral powder

**Medication Description:** Palforzia, an oral immunotherapy, is indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. It is approved for use in patients with a confirmed diagnosis of peanut allergy. Palforzia is to be used in conjunction with a peanut-avoidant diet. It is not indicated for the emergency treatment of allergic reactions, including anaphylaxis. Prior to initiation, the prescriber should verify that the patient has injectable epinephrine and has been instructed on its appropriate use.

**Covered Uses:** The mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.

**Exclusion Criteria:**

1. Emergency treatment of allergic reactions, including anaphylaxis.
2. Patients with uncontrolled asthma
3. Patients with a history of eosinophilic esophagitis and other eosinophilic gastrointestinal disease

**Required Medical Information:**

1. Diagnosis
2. Current medications
3. Positive skin prick test (SPT)
4. Positive in vitro test (i.e., a blood test) for peanut-specific IgE

**Age Restrictions:** 4 years of age and older

**Prescriber Restrictions:** Prescribed by, or in consultation with, an allergist or immunologist.

**Coverage Duration:** 12 months

**Other Criteria:**

1. The patient has a history of an allergic reaction to peanut that meets each of the following (a, b, and c):
  - a. The patient demonstrated signs and symptoms of a significant systemic allergic reaction; **AND**
  - b. This reaction occurred within a short period of time following a known ingestion of peanut or peanut-containing food; **AND**
  - c. The prescriber deemed this reaction significant enough to require a prescription for an epinephrine auto-injector; **AND**
2. The patient has a positive skin prick test (SPT) response to peanut with a wheal diameter  $\geq 3$  mm larger than the negative control; **AND**
3. The patient has a positive in vitro test (i.e., a blood test) for peanut-specific IgE with a level  $\geq 0.35$  kUA/L; **AND**
4. Palforzia will be used in conjunction with a peanut-avoidant diet.

Last Res. June 2020



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

**References:**

1. Palforzia® allergen powder [prescribing information]. Brisbane, CA: Aimmune Therapeutics; January 2020.

<b>Rev #</b>	<b>Type of Change</b>	<b>Summary of Change</b>	<b>Sections Affected</b>	<b>Date</b>
1	New Policy	New Policy	All	6/3/2020